Patents Assigned to ROYAN INSTITUTE
  • Patent number: 10962518
    Abstract: A method and apparatus for drug dissolution testing may include an overflow vessel with an overflow outlet port at a predetermined height from a bottom of the overflow vessel, a first water bath submerging the overflow vessel and configured to keep a temperature of the overflow vessel at a first predetermined temperature, a pressurized vessel containing a dissolution medium, a second water bath submerging the pressurized vessel and configured to keep the dissolution medium at a second predetermined temperature, a dissolution medium path with an output end connected in fluid communication with the flow cell and an input end attached in fluid communication to the pressurized vessel, where the dissolution medium path may transfer the dissolution medium from the pressurized vessel into the flow cell, a collection vessel connected to the overflow outlet port of the flow cell, and a third water bath submerging the collection vessel and configured to keep the collection vessel at a third predetermined temperature.
    Type: Grant
    Filed: October 28, 2018
    Date of Patent: March 30, 2021
    Assignees: ROYAN INSTITUTE, IRAN POLYMER AND PETROCHEMICAL INSTITUTE
    Inventors: Hamid Gourabi, Hamid Mobedi, Siyavash Mirzaei, Sakineh Khezli
  • Publication number: 20190211087
    Abstract: An antibody or fragment thereof capable of binding to a neurotoxic tau protein. The neurotoxic tau protein includes a phosphorylation site at threonine residue 231 in AT180 domain of tau proteins and an amino acid substitution of proline residue 232 to glycine (P232G) in AT180 domain of tau proteins.
    Type: Application
    Filed: March 11, 2019
    Publication date: July 11, 2019
    Applicants: Royan Institute
    Inventor: Koorosh Shahpasand
  • Publication number: 20190177689
    Abstract: A method for isolating oogonial stem cells (OSCs) including forming an ovarian cell suspension from an ovary, forming ovaroids by culturing the ovarian cell suspension in a three-dimensional culture, and migrating the OSCs around the ovaroids by culturing the ovaroids on a mouse embryonic fibroblast (MEF)-coated plate.
    Type: Application
    Filed: December 10, 2018
    Publication date: June 13, 2019
    Applicant: Royan Institute
    Inventors: Hossein Baharvand, Maryam Saber, Fereshteh Esfandiari Nezhad
  • Publication number: 20190101518
    Abstract: A method and apparatus for drug dissolution testing may include an overflow vessel with an overflow outlet port at a predetermined height from a bottom of the overflow vessel, a first water bath submerging the overflow vessel and configured to keep a temperature of the overflow vessel at a first predetermined temperature, a pressurized vessel containing a dissolution medium, a second water bath submerging the pressurized vessel and configured to keep the dissolution medium at a second predetermined temperature, a dissolution medium path with an output end connected in fluid communication with the flow cell and an input end attached in fluid communication to the pressurized vessel, where the dissolution medium path may transfer the dissolution medium from the pressurized vessel into the flow cell, a collection vessel connected to the overflow outlet port of the flow cell, and a third water bath submerging the collection vessel and configured to keep the collection vessel at a third predetermined temperature.
    Type: Application
    Filed: October 28, 2018
    Publication date: April 4, 2019
    Applicants: Royan Institute, Iran Polymer and Petrochemical Institute
    Inventors: Hamid Gourabi, Hamid Mobedi, Siyavash Mirzaei, Sakineh Khezli
  • Publication number: 20180155680
    Abstract: A method for derivation and maintenance of pluripotency in mouse embryonic stem (mES) cells is disclosed. The method includes isolating mES cells from mouse embryos in a culture medium including an R2i compound, and culturing the mES cells in a medium including the R2i compound or a transforming growth factor beta (TGF-?) signaling pathway inhibitor. The R2i compound includes combination of a transforming growth factor beta (TGF-?) signaling pathway inhibitor and an extracellular signal-regulated kinases (ERK) signaling pathway inhibitor. This method can facilitate the homogeneous expression of pluripotency factors in embryonic stem cells.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 7, 2018
    Applicant: Royan Institute
    Inventors: Hossein Baharvand, Seyedeh Nafiseh Hasani, Mehdi Totonchi, Hamid Gourabi
  • Publication number: 20150037883
    Abstract: The various embodiments herein provide a method for derivation and long term establishment of ground state pluripotent embryonic stem cells. Further the embodiments herein provides a method to inhibit the ERK and TGF ? signalling pathways for long term maintenance of the embryonic stem cells. The R2i mouse embryonic stem (ES) cells are derived from 3.5 day blastocysts. The mouse ES cells are cultured in media containing R2i and 2i inhibitors of ERK and TGF ? pathways. The ES cells are subjected to in vitro and in vivo differentiation. The ES cells are subjected to RT-PCR and qRT-PCR, flow cytometry and karyotyping. The result reveals that the R2i maintains the ground state of ES cells and self renewal. Also R2i increases embryonic cleavage and clonal propagation of ES. Further R2i asserts genomic integrity and pluripotency of ES.
    Type: Application
    Filed: August 19, 2014
    Publication date: February 5, 2015
    Applicant: ROYAN INSTITUTE
    Inventors: Hossein Baharvand, Seyedeh Nafiseh Nafiseh Hasani, Mehdi Totonchi, Hamid Gourabi